共 101 条
[11]
Lissen E(2017)2017 ESC/EACTS guidelines for the management of valvular heart disease Eur Heart J 60 836-E288
[12]
Clumeck N(2016)2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC Eur Heart J 60 1438-2247
[13]
Park HJ(2019)Detection of pulmonary hypertension with systolic pressure estimated by doppler echocardiography Int Heart J 31 E282-601
[14]
Park JY(2012)Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research consortium-2 consensus document J Am Coll Cardiol 8 2240-39
[15]
Jung SM(2019)Surgical risk scores applied to transcatheter aortic valve implantation: friends or foes? short-term and long-term outcomes from a single-center registry J Invasive Cardiol 12 591-877
[16]
Kim M(2021)Fibrosis-4 index reflects right ventricular function and prognosis in heart failure with preserved ejection fraction ESC Heart Fail 176 32-1192
[17]
Jun DW(2019)Pulmonary hypertension in patients with severe aortic stenosis: prognostic impact after transcatheter aortic valve replacement: pulmonary hypertension in patients undergoing TAVR JACC Cardiovasc Imaging 62 869-1137
[18]
Park H(2014)Increased mortality after transcatheter aortic valve implantation (TAVI) in patients with severe aortic stenosis and low ejection fraction: a meta-analysis of 6898 patients Int J Cardiol 14 1181-751
[19]
Kang BK(2013)Prognostic value of chronic kidney disease after transcatheter aortic valve implantation J Am Coll Cardiol 13 1135-526
[20]
Sumida Y(2021)Effect of transcatheter aortic valve replacement on concomitant mitral regurgitation and its impact on mortality JACC Cardiovasc Interv 112 740-854